Andrea Rigamonti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrea Rigamonti has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Agostino Consoli
Department of Medicine and Ageing Sciences and CAST, University G. d’Annunzio di Chieti-Pescara, Chieti , Italy
1 shared publication - Andrea Enzo Scaramuzza
Paediatrics Unit, ASST Cremona, Maggiore Hospital, Cremona, Italy
1 shared publication Andrea Laurenzi
San Raffaele Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
1 shared publicationAngela Zanfardino
Department of Pediatrics, Regional Center of Pediatric Diabetology “G.Stoppoloni”, University of Campania “Luigi Vanvitelli”, Naples, Italy
1 shared publicationAntonio Rossi
Division of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy
1 shared publicationBarbara Felappi
U.S. Auxoendocrinologia pediatrica, U.O.C Pediatria-Clinica Pediatrica, ASST Spedali Civili, Brescia, Italy
1 shared publication
Latest Publications
- Open Access
- 14 September 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (12) , 11032-11041
Practical Guidance for the Use of Control‐ IQ Technology During Physical Activity and Exercise
Introduction: Use of automated insulin delivery (AID) systems during physical activity and exercise (PA) is safe and associated with improved glucose outcomes when compared with insulin pump therapy in manual mode and insulin pen therapy, provided that appropriate adjustments to insulin doses and carbohydrate intake are ensured. Aim: This expert guidance aimed to support healthcare professionals in educating Control‐IQ (Tandem Diabetes Care) users on PA management. Methods: Based on international recommendations, including the recent EASD/ISPAD position statement on AID and exercise, as well as on the authors' clinical experience, we developed practical flowcharts and accompanying information that provide step‐by‐step guidance for PA management in children, adolescents and adults with type 1 diabetes using the Control‐IQ technology. Results: Operational instructions were outlined across four different scenarios, with additional advice on insulin pump suspension where required. In each of the scenarios, we highlighted the possibility of activating a Personal Profile with more or less insulin, a unique feature of the Control‐IQ algorithm that can be used simultaneously with the Exercise Activity feature. Conclusion: We believe that this expert guidance, with its practical flowcharts, can help simplify decision‐making for Control‐IQ users.
- 14 September 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (12) , 11032-11041
Open AccessPractical Guidance for the Use of Control‐ IQ Technology During Physical Activity and Exercise
Introduction: Use of automated insulin delivery (AID) systems during physical activity and exercise (PA) is safe and associated with improved glucose outcomes when compared with insulin pump therapy in manual mode and insulin pen therapy, provided that appropriate adjustments to insulin doses and carbohydrate intake are ensured. Aim: This expert guidance aimed to support healthcare professionals in educating Control‐IQ (Tandem Diabetes Care) users on PA management. Methods: Based on international recommendations, including the recent EASD/ISPAD position statement on AID and exercise, as well as on the authors' clinical experience, we developed practical flowcharts and accompanying information that provide step‐by‐step guidance for PA management in children, adolescents and adults with type 1 diabetes using the Control‐IQ technology. Results: Operational instructions were outlined across four different scenarios, with additional advice on insulin pump suspension where required. In each of the scenarios, we highlighted the possibility of activating a Personal Profile with more or less insulin, a unique feature of the Control‐IQ algorithm that can be used simultaneously with the Exercise Activity feature. Conclusion: We believe that this expert guidance, with its practical flowcharts, can help simplify decision‐making for Control‐IQ users.
- 17 July 2026
- Published by SAGE Publications in Diabetes Technology & Therapeutics
Three-Year Durability of Automated Insulin Delivery Therapy in Children and Adolescents with Type 1 Diabetes: A Multicenter Real-World Study
Introduction: Evidence on the long-term durability of glycemic control beyond the first year of automated insulin delivery therapy remains limited, particularly in large multicenter pediatric cohorts. The present study aimed to evaluate long-term effectiveness and identify determinants of sustained optimal outcomes over 3 years of MiniMed™ 780G use in youth with type 1 diabetes (T1D). Materials and Methods: In this longitudinal, multicenter, real-world study, 359 youth with T1D (median age 12.2 years, 50.9% female) from 20 Italian pediatric diabetes centers were followed for 3 years after MiniMed 780G initiation. Glucose metrics, insulin delivery parameters, device settings, and engagement indicators were analyzed at 1, 2, and 3 years. Longitudinal changes were assessed using linear mixed-effects models. Multivariable logistic regression identified predictors of achieving time in tight range target (TITR ≥ 50%) at 3 years. Results: Median time in range (TIR) remained within international targets but declined modestly from 75% at 1 year to 74% at 3 years ( P = 0.002). The percentage of automatic correction boluses increased over time, whereas user-initiated boluses and carbohydrate entries declined ( P < 0.001). Youth with higher TIR at 1 year showed a progressive reduction in TIR and greater increase in automated corrections (time × group interaction P < 0.001). At 3 years, higher SmartGuard use (odds ratio [OR]: 1.13, 95% confidence interval [CI]: 1.03–1.23; P = 0.007), optimal system settings (OR: 3.21, 95% CI: 1.33–7.77; P = 0.010), and lower automatic correction boluses (OR: 0.84, 95% CI: 0.80–0.89; P < 0.001) were independently associated with achieving TITR ≥50%. Conclusions: MiniMed 780G provides sustained glycemic control over 3 years. However, progressive reliance on automated corrections and reduced user engagement may attenuate tight glycemic control, highlighting the need for ongoing education and proactive device optimization.
- 17 July 2026
- Published by SAGE Publications in Diabetes Technology & Therapeutics
Three-Year Durability of Automated Insulin Delivery Therapy in Children and Adolescents with Type 1 Diabetes: A Multicenter Real-World Study
Introduction: Evidence on the long-term durability of glycemic control beyond the first year of automated insulin delivery therapy remains limited, particularly in large multicenter pediatric cohorts. The present study aimed to evaluate long-term effectiveness and identify determinants of sustained optimal outcomes over 3 years of MiniMed™ 780G use in youth with type 1 diabetes (T1D). Materials and Methods: In this longitudinal, multicenter, real-world study, 359 youth with T1D (median age 12.2 years, 50.9% female) from 20 Italian pediatric diabetes centers were followed for 3 years after MiniMed 780G initiation. Glucose metrics, insulin delivery parameters, device settings, and engagement indicators were analyzed at 1, 2, and 3 years. Longitudinal changes were assessed using linear mixed-effects models. Multivariable logistic regression identified predictors of achieving time in tight range target (TITR ≥ 50%) at 3 years. Results: Median time in range (TIR) remained within international targets but declined modestly from 75% at 1 year to 74% at 3 years ( P = 0.002). The percentage of automatic correction boluses increased over time, whereas user-initiated boluses and carbohydrate entries declined ( P < 0.001). Youth with higher TIR at 1 year showed a progressive reduction in TIR and greater increase in automated corrections (time × group interaction P < 0.001). At 3 years, higher SmartGuard use (odds ratio [OR]: 1.13, 95% confidence interval [CI]: 1.03–1.23; P = 0.007), optimal system settings (OR: 3.21, 95% CI: 1.33–7.77; P = 0.010), and lower automatic correction boluses (OR: 0.84, 95% CI: 0.80–0.89; P < 0.001) were independently associated with achieving TITR ≥50%. Conclusions: MiniMed 780G provides sustained glycemic control over 3 years. However, progressive reliance on automated corrections and reduced user engagement may attenuate tight glycemic control, highlighting the need for ongoing education and proactive device optimization.